Blue Trust Inc. Lowers Stock Holdings in Sanofi (NASDAQ:SNY)

Blue Trust Inc. reduced its position in shares of Sanofi (NASDAQ:SNY) by 33.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,098 shares of the company’s stock after selling 5,948 shares during the period. Blue Trust Inc.’s holdings in Sanofi were worth $583,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. V Square Quantitative Management LLC boosted its position in shares of Sanofi by 30.6% during the fourth quarter. V Square Quantitative Management LLC now owns 13,557 shares of the company’s stock worth $657,000 after buying an additional 3,179 shares during the period. McClarren Financial Advisors Inc. boosted its position in shares of Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Van ECK Associates Corp boosted its position in shares of Sanofi by 18.1% during the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock worth $31,965,000 after buying an additional 101,726 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Sanofi by 128.0% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company’s stock worth $5,558,000 after buying an additional 64,747 shares during the period. Finally, Kentucky Trust Co purchased a new position in Sanofi in the fourth quarter valued at $436,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $60.00.

Sanofi Stock Up 0.9 %

Shares of NASDAQ SNY opened at $54.50 on Monday. The company has a market capitalization of $138.31 billion, a price-to-earnings ratio of 21.89, a price-to-earnings-growth ratio of 0.99 and a beta of 0.57. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The business has a 50-day moving average of $50.30 and a two-hundred day moving average of $52.45. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. On average, analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.